Recomendaciones médicas para uveítis no infecciosas en adultos

Autores/as

  • Carlos León-Céspedes Caja Costarricense de Seguro Social, Hospital San Juan de Dios
  • María del Rosario Espinoza-Mora Universidad de Costa Rica
  • Fabián Antillón-Flores Caja Costarricense de Seguro Social, Hospital Dr. Rafael Ángel Calderón Guardia
  • Natalia Bolaños-Araya Caja Costarricense de Seguro Social, Hospital Maximiliano Peralta Jiménez
  • Henry Chan-Chen Caja Costarricense de Seguro Social, Hospital México
  • Hilda Mena-González Caja Costarricense de Seguro Social, Hospital San Juan de Dios
  • Arturo Runnebaum-Jiménez Caja Costarricense de Seguro Social, Hospital San Juan de Dios
  • Raquel Jiménez-Solís Caja Costarricense de Seguro Social, Hospital San Juan de Dios
  • Adolfo Pacheco-Salazar Caja Costarricense de Seguro Social, Hospital Dr. Rafael Ángel Calderón Guardia
  • Mónica Evans-Tinoco Centro Médico Momentum
  • María Paz León-Bratti Caja Costarricense de Seguro Social, Hospital México

DOI:

https://doi.org/10.51481/amc.v62i1.1057

Palabras clave:

uveítis no infecciosa, inflamación ocular, autoinmunidad, inmunoterapia, atarata uveítica

Resumen

Justificación: las uveítis no infecciosas constituyen una importante causa de pérdida visual a nivel mundial; por su complejidad y gravedad de complicaciones requieren un abordaje temprano y multidisciplinario. En Costa Rica se desconoce hasta el momento la incidencia global de estas entidades y todavía no existe ningún consenso en cuanto a su manejo.

Objetivos: resumir las recomendaciones terapéuticas vigentes para uveítis no infecciosas en adultos y ofrecer una guía adaptada a la realidad costarricense.

Métodos: se efectuó una revisión no sistemática de bibliografía médica indexada en las plataformas PubMed y Scielo, sobre el manejo médico de las uveítis no infecciosas. De igual manera, se compararon los esquemas terapéuticos recomendados actualmente en América y Europa con el abordaje realizado en los centros hospitalarios costarricenses, para crear una guía adaptada a la realidad nacional. En la elaboración de estas recomendaciones participaron médicos especialistas de todas las clínicas multidisciplinarias especializadas en uveítis del país.

Conclusiones: en Costa Rica se cuenta con la mayoría de las opciones disponibles para el tratamiento de uveítis idiopáticas en el sistema público de salud. Se logró la creación de algoritmos de tratamiento para las diferentes patologías.

Descriptores: uveítis no infecciosa, inflamación ocular, autoinmunidad, inmunoterapia, catarata uveítica.

Descargas

Los datos de descargas todavía no están disponibles.

Citas

Pasadhika S, Rosenbaum JT. Update on the use of systemic biologic agents in the treatment of noninfectious uveitis. Biologics : targets & therapy. 2014;8:67-81.

Bloch-Michel E, Nussenblatt RB. International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory disease. Am J Ophthalmol. 1987;103(2):234-5.

Okada AA, Jabs DA. The standardization of uveitis nomenclature project: the future is here. JAMA Ophthalmol. 2013;131(6):787-9.

Sen ES, Dick AD, Ramanan AV. Uveitis associated with juvenile idiopathic arthritis. Nat Rev Rheumatol. 2015;11(6):338-48.

Tsirouki T, Dastiridou A, Symeonidis C, Tounakaki O, Brazitikou I, Kalogeropoulos C, et al. A Focus on the Epidemiology of Uveitis. Ocul Immunol Inflamm. 2018;26(1):2-16.

Espinoza Mora MdR, Chan-Cheng, Henry Chihong, Dorado-Quesada C, León-Bratti MP. Casos clínicos de uveítis del Hospital México, 2010-2013. Acta Médica Costarricense. 2016;58:74-80.

Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis Nomenclature Working G. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140(3):509-16.

Álvarez-Mon Soto M, Albarrán F, Gorroño M, Pérez Gómez A. Uveítis: etiopatogenia, diagnóstico y tratamiento. Medicine - Programa de Formación Médica Continuada Acreditado. 2017;12(28):1645-53.

Seve P, Cacoub P, Bodaghi B, Trad S, Sellam J, Bellocq D, et al. Uveitis: Diagnostic work-up. A literature review and recommendations from an expert committee. Autoimmunity reviews. 2017;16(12):1254-64.

Jancevski M, Foster CS. Cataracts and uveitis. Curr Opin Ophthalmol. 2010;21(1):10-4.

Moorthy RAmS, Mermoud ANd, Baerveldt G, Minckler DS, Lee PP, Rao NArA. Glaucoma associated with uveitis. Survey of Ophthalmology. 1997;41(5):361-94.

Tran THC, de Smet MD, Bodaghi B, Fardeau C, Cassoux N, Lehoang P. Uveitic macular oedema: correlation between optical coherence tomography patterns with visual acuity and fluorescein angiography. British Journal of Ophthalmology. 2008;92(7):922-7.

Jabs DA, Busingye J. Approach to the diagnosis of the uveitides. Am J Ophthalmol. 2013;156(2):228-36.

Calvo Hernández LM, Bautista Salinas RM, Suárez Cabrera M. Uveítis: Un reto para el internista. Anales de Medicina Interna. 2008;25:141-8.

Hajj-Ali RA, Lowder C, Mandell BF. Uveitis in the internist’s office: are a patient’s eye symptoms serious? Cleveland Clinic journal of medicine. 2005;72(4):329-39.

Foster CS, Kothari S, Anesi SD, Vitale AT, Chu D, Metzinger JL, et al. The Ocular Immunology and Uveitis Foundation preferred practice patterns of uveitis management. Surv Ophthalmol. 2016;61(1):1-17.

Pato E, Martin-Martinez MA, Castello A, Mendez-Fernandez R, Munoz-Fernandez S, Cordero-Coma M, et al. Development of an activity disease score in patients with uveitis (UVEDAI). Rheumatol Int. 2017;37(4):647-56.

Jabs DA. Immunosuppression for the Uveitides. Ophthalmology. 2018;125(2):193-202.

Schwartzman S. Advancements in the management of uveitis. Best Pract Res Clin Rheumatol. 2016;30(2):304-15.

Islam N, Pavesio C. Uveitis (acute anterior). BMJ Clin Evid. 2010;2010.

Kempen JH, Altaweel MM, Drye LT, Holbrook JT, Jabs DA, Sugar EA, et al. Benefits of Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study. Ophthalmology. 2015;122(10):1967-75.

Brady CJ, Villanti AC, Law HA, Rahimy E, Reddy R, Sieving PC, et al. Corticosteroid implants for chronic non-infectious uveitis. Cochrane Database Syst Rev. 2016;2:CD010469.

Trial WCftMUST, Group F-uSR. Association Between Long-Lasting Intravitreous Fluocinolone Acetonide Implant vs Systemic Anti-inflammatory Therapy and Visual Acuity at 7 Years Among Patients With Intermediate, Posterior, or PanuveitisIntraocular vs Systemic Therapy for UveitisIntraocular vs Systemic Therapy for Uveitis. JAMA. 2017;317(19):1993-2005.

Durrani K, Zakka FR, Ahmed M, Memon M, Siddique SS, Foster CS. Systemic therapy with conventional and novel immunomodulatory agents for ocular inflammatory disease. Surv Ophthalmol. 2011;56(6):474-510.

Gangaputra S, Newcomb CW, Liesegang TL, Kacmaz RO, Jabs DA, Levy-Clarke GA, et al. Methotrexate for ocular inflammatory diseases. Ophthalmology. 2009;116(11):2188-98 e1.

Samson CM, Waheed N, Baltatzis S, Foster CS. Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology. 2001;108(6):1134-9.

Weber-Schoendorfer C, Chambers C, Wacker E, Beghin D, Bernard N, Shechtman S, et al. Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study. Arthritis & rheumatology (Hoboken, NJ). 2014;66(5):1101-10.

Pasadhika S, Kempen JH, Newcomb CW, Liesegang TL, Pujari SS, Rosenbaum JT, et al. Azathioprine for ocular inflammatory diseases. Am J Ophthalmol. 2009;148(4):500-9 e2.

Rossi DC, Ribi C, Guex-Crosier Y. Treatment of chronic non-infectious uveitis and scleritis. Swiss Med Wkly. 2019;149:w20025.

Baltatzis S, Tufail F, Yu EN, Vredeveld CM, Foster CS. Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders. Ophthalmology. 2003;110(5):1061-5.

Deuter CME, Engelmann K, Heiligenhaus A, Lanzl I, Mackensen F, Ness T, et al. Enteric-coated mycophenolate sodium in the treatment of non-infectious intermediate uveitis: results of a prospective, controlled, randomised, open-label, early terminated multicentre trial. Br J Ophthalmol. 2018;102(5):647-53.

Rodriguez EEC, Sakata VM, Cavalcanti DCTM, Zaghetto JM, Olivalves E, Hirata CE, et al. Mycophenolate mofetil as an immunomodulator in refractory noninfectious uveitis. Arquivos Brasileiros de Oftalmologia. 2016;79:369-72.

Sobrin L, Christen W, Foster CS. Mycophenolate mofetil after methotrexate failure or intolerance in the treatment of scleritis and uveitis. Ophthalmology. 2008;115(8):1416-21, 21 e1.

Kacmaz RO, Kempen JH, Newcomb C, Daniel E, Gangaputra S, Nussenblatt RB, et al. Cyclosporine for ocular inflammatory diseases. Ophthalmology. 2010;117(3):576-84.

Mochizuki M, Masuda K, Sakane T, Ito K, Kogure M, Sugino N, et al. A clinical trial of FK506 in refractory uveitis. Am J Ophthalmol. 1993;115(6):763-9.

Murphy CC, Greiner K, Plskova J, Duncan L, Frost NA, Forrester JV, et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Arch Ophthalmol. 2005;123(5):634-41.

Lee RW, Greenwood R, Taylor H, Amer R, Biester S, Heissigerova J, et al. A randomized trial of tacrolimus versus tacrolimus and prednisone for the maintenance of disease remission in noninfectious uveitis. Ophthalmology. 2012;119(6):1223-30.

Pujari SS, Kempen JH, Newcomb CW, Gangaputra S, Daniel E, Suhler EB, et al. Cyclophosphamide for ocular inflammatory diseases. Ophthalmology. 2010;117(2):356-65.

Galor A, Jabs DA, Leder HA, Kedhar SR, Dunn JP, Peters GB, III, et al. Comparison of Antimetabolite Drugs as Corticosteroid-Sparing Therapy for Noninfectious Ocular Inflammation. Ophthalmology. 2008;115(10):1826-32.

Knickelbein JE, Kim M, Argon E, Nussenblatt RB, Sen NH. Comparative efficacy of steroid-sparing therapies for non-infectious uveitis. Expert Rev Ophthalmol. 2017;12(4):313-9.

Rodrigues EB, Farah ME, Maia M, Penha FM, Regatieri C, Melo GB, et al. Therapeutic monoclonal antibodies in ophthalmology. Prog Retin Eye Res. 2009;28(2):117-44.

Kahn P, Weiss M, Imundo LF, Levy DM. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology. 2006;113(5):860-4 e2.

Sfikakis PP, Kaklamanis PH, Elezoglou A, Katsilambros N, Theodossiadis PG, Papaefthimiou S, et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behcet disease. Ann Intern Med. 2004;140(5):404-6.

Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN. Effect of infliximab on sight-threatening panuveitis in Behcet’s disease. Lancet. 2001;358(9278):295-6.

Baughman RP, Bradley DA, Lower EE. Infliximab in chronic ocular inflammation. Int J Clin Pharmacol Ther. 2005;43(1):7-11.

Pasadhika S, Suhler EB, T. CE. Use of Biologic Agents in the Treatment of Uveitis. Review of Ophthalmology. 2010:46-52.

Bodaghi B, Bui Quoc E, Wechsler B, Tran THC, Cassoux N, Le Thi Huong D, et al. Therapeutic use of infliximab in sight threatening uveitis: retrospective analysis of efficacy, safety, and limiting factors. Annals of the Rheumatic Diseases. 2005;64(6):962-4.

Heiligenhaus A, Minden K, Tappeiner C, Baus H, Bertram B, Deuter C, et al. Update of the evidence based, interdisciplinary guideline for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Semin Arthritis Rheum. 2018.

Ramanan AV, Dick AD, Jones AP, McKay A, Williamson PR, Compeyrot-Lacassagne S, et al. Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis. N Engl J Med. 2017;376(17):1637-46.

Simonini G, Taddio A, Cattalini M, Caputo R, de Libero C, Parentin F, et al. Superior efficacy of Adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: Adalimumab as starting anti-TNF-α therapy in childhood chronic uveitis. Pediatric rheumatology online journal. 2013;11:16-.

Bawazeer A, Raffa LH, Nizamuddin SH. Clinical experience with adalimumab in the treatment of ocular Behcet disease. Ocul Immunol Inflamm. 2010;18(3):226-32.

Suhler EB, Lowder CY, Goldstein DA, Giles T, Lauer AK, Kurz PA, et al. Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial. Br J Ophthalmol. 2013;97(4):481-6.

Alokaily F, Al Saati A, Jawad A. Successful treatment of Behcet’s uveitis with Tocilizumab. Saudi J Ophthalmol. 2017;31(1):42-4.

Calvo-Rio V, Santos-Gomez M, Calvo I, Gonzalez-Fernandez MI, Lopez-Montesinos B, Mesquida M, et al. Anti-Interleukin-6 Receptor Tocilizumab for Severe Juvenile Idiopathic Arthritis-Associated Uveitis Refractory to Anti-Tumor Necrosis Factor Therapy: A Multicenter Study of Twenty-Five Patients. Arthritis & rheumatology (Hoboken, NJ). 2017;69(3):668-75.

Silpa-Archa S, Oray M, Preble JM, Foster CS. Outcome of tocilizumab treatment in refractory ocular inflammatory diseases. Acta Ophthalmol. 2016;94(6):e400-6.

Tappeiner C, Heinz C, Ganser G, Heiligenhaus A. Is Tocilizumab an Effective Option for Treatment of Refractory Uveitis Associated with Juvenile Idiopathic Arthritis? The Journal of Rheumatology. 2012;39(6):1294-5.

Adan A, Mesquida M, Llorenc V, Espinosa G, Molins B, Hernandez MV, et al. Tocilizumab treatment for refractory uveitis-related cystoid macular edema. Graefes Arch Clin Exp Ophthalmol. 2013;251(11):2627-32.

Miserocchi E, Modorati G, Berchicci L, Pontikaki I, Meroni P, Gerloni V. Long-term treatment with rituximab in severe juvenile idiopathic arthritis-associated uveitis. Br J Ophthalmol. 2016;100(6):782-6.

Thomas AS. Biologics for the treatment of noninfectious uveitis: current concepts and emerging therapeutics. Curr Opin Ophthalmol. 2019;30(3):138-50.

Calvo-Rio V, Blanco R, Santos-Gomez M, Rubio-Romero E, Cordero-Coma M, Gallego-Flores A, et al. Golimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 15 patients. Semin Arthritis Rheum. 2016;46(1):95-101.

Chaparro Sanabria JA, Bautista Molano W, Valle Oñate R. Tratamiento de uveítis y espondilitis anquilosante refractaria a tres medicamentos inhibidores de factor de necrosis tumoral alfa con golimumab. Reumatología Clínica.

Fabiani C, Sota J, Rigante D, Vitale A, Emmi G, Vannozzi L, et al. Rapid and Sustained Efficacy of Golimumab in the Treatment of Multirefractory Uveitis Associated with Behcet’s Disease. Ocul Immunol Inflamm. 2019;27(1):58-63.

Palmou-Fontana N, Calvo-Rio V, Martin-Varillas JL, Fernandez-Diaz C, Mesquida M, Adan A, et al. Golimumab in refractory uveitis associated to juvenile idiopathic arthritis: multicentre study of 7 cases and literature review. Clinical and experimental rheumatology. 2018;36(4):652-7.

Yazgan S, Celik U, Isik M, Yesil NK, Baki AE, Sahin H, et al. Efficacy of golimumab on recurrent uveitis in HLA-B27-positive ankylosing spondylitis. Int Ophthalmol. 2017;37(1):139-45.

Burkholder BM. Vogt-Koyanagi-Harada disease. Curr Opin Ophthalmol. 2015;26(6):506-11.

Du L, Kijlstra A, Yang P. Vogt-Koyanagi-Harada disease: Novel insights into pathophysiology, diagnosis and treatment. Progress in Retinal and Eye Research. 2016;52:84-111.

Lai TY, Chan RP, Chan CK, Lam DS. Effects of the duration of initial oral corticosteroid treatment on the recurrence of inflammation in Vogt-Koyanagi-Harada disease. Eye (Lond). 2009;23(3):543-8.

Cuchacovich M, Solanes F, Diaz G, Cermenati T, Avila S, Verdaguer J, et al. Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic vogt-koyanagi-harada disease. Ocul Immunol Inflamm. 2010;18(3):200-7.

Kim SJ, Yu HG. The Use of Low-Dose Azathioprine in Patients with Vogt-Koyanagi-Harada Disease. Ocular Immunology and Inflammation. 2007;15(5):381-7.

Urzua CA, Velasquez V, Sabat P, Berger O, Ramirez S, Goecke A, et al. Earlier immunomodulatory treatment is associated with better visual outcomes in a subset of patients with Vogt-Koyanagi-Harada disease. Acta Ophthalmologica. 2015;93(6):e475-e80.

Wu L, Evans T, Saravia M, Schlaen A, Couto C. Intravitreal bevacizumab for choroidal neovascularization secondary to Vogt-Koyanagi-Harada syndrome. Jpn J Ophthalmol. 2009;53(1):57-60.

Hatemi G, Christensen R, Bang D, Bodaghi B, Celik AF, Fortune F, et al. 2018 update of the EULAR recommendations for the management of Behcet’s syndrome. Ann Rheum Dis. 2018;77(6):808-18.

Akman-Demir G, Ayranci O, Kurtuncu M, Vanli EN, Mutlu M, Tugal-Tutkun I. Cyclosporine for Behcet’s uveitis: is it associated with an increased risk of neurological involvement? Clinical and experimental rheumatology. 2008;26(4 Suppl 50):S84-90.

Kötter I, Günaydin I, Batra M, Vonthein R, Stübiger N, Fierlbeck G, et al. CNS involvement occurs more frequently in patients with Behçet’s disease under cyclosporin A (CSA) than under other medications—results of a retrospective analysis of 117 cases. Clinical Rheumatology. 2006;25(4):482-6.

Jaffe GJ, Dick AD, Brezin AP, Nguyen QD, Thorne JE, Kestelyn P, et al. Adalimumab in Patients with Active Noninfectious Uveitis. N Engl J Med. 2016;375(10):932-43.

Nguyen QD, Merrill PT, Jaffe GJ, Dick AD, Kurup SK, Sheppard J, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016;388(10050):1183-92.

Takeuchi M, Kezuka T, Sugita S, Keino H, Namba K, Kaburaki T, et al. Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behcet’s disease: a multicenter study. Ophthalmology. 2014;121(10):1877-84.

Vallet H, Riviere S, Sanna A, Deroux A, Moulis G, Addimanda O, et al. Efficacy of anti-TNF alpha in severe and/or refractory Behçet’s disease: Multicenter study of 124 patients. Journal of Autoimmunity. 2015;62:67-74.

Yang SJ, Salek S, Rosenbaum JT. Ocular sarcoidosis: new diagnostic modalities and treatment. Curr Opin Pulm Med. 2017;23(5):458-67.

Rochepeau C, Jamilloux Y, Kerever S, Febvay C, Perard L, Broussolle C, et al. Long-term visual and systemic prognoses of 83 cases of biopsy-proven sarcoid uveitis. Br J Ophthalmol. 2017;101(7):856-61.

Ma SP, Rogers SL, Hall AJ, Hodgson L, Brennan J, Stawell RJ, et al. Sarcoidosis-related Uveitis: Clinical Presentation, Disease Course, and Rates of Systemic Disease Progression After Uveitis Diagnosis. Am J Ophthalmol. 2019;198:30-6.

Jamilloux Y, Kodjikian L, Broussolle C, Seve P. Sarcoidosis and uveitis. Autoimmunity reviews. 2014;13(8):840-9.

Maneiro JR, Salgado E, Gomez-Reino JJ, Carmona L, Group BS. Efficacy and safety of TNF antagonists in sarcoidosis: data from the Spanish registry of biologics BIOBADASER and a systematic review. Semin Arthritis Rheum. 2012;42(1):89-103.

Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75(9):1583-94.

Hassan RI, Gaffo AL. Rituximab in ANCA-Associated Vasculitis. Curr Rheumatol Rep. 2017;19(2):6.

Kubal AA, Perez VL. Ocular manifestations of ANCA-associated vasculitis. Rheum Dis Clin North Am. 2010;36(3):573-86.

Wegener’s Granulomatosis Etanercept Trial Research G. Etanercept plus standard therapy for Wegener’s granulomatosis. N Engl J Med. 2005;352(4):351-61.

Lyon F, Gale RP, Lightman S. Recent developments in the treatment of uveitis: an update. Expert Opin Investig Drugs. 2009;18(5):609-16.

Díaz-Coto J, Molina-Guevara E, Chaverri-Oreamuno L, Monge-Zeledón P, Contreras-Arias J, Méndez-Ceciliano M, et al. Valoración previa a la inmunosupresión farmacológica en Reumatología. Acta Médica Costarricense. 2017;59:153-7.

Oldfield V, Dhillon S, Plosker GL. Tocilizumab. Drugs. 2009;69(5):609-32.

Toro-Arango O, De-la-Torre A, Pachón-Suárez D, Salazar-Muñoz J, Parra-Morales A. Diagnóstico y tratamiento inicial de la uveítis por médicos no oftalmólogos. Nova. 2017;15:99-114.

Rathinam SR, Babu M. Algorithmic approach in the diagnosis of uveitis. Indian J Ophthalmol. 2013;61(6):255-62.

Airody A, Heath G, Lightman S, Gale R. Non-Infectious Uveitis: Optimising the Therapeutic Response. Drugs. 2016;76(1):27-39.

Burkholder BM, Ramulu PY. Improving More Than Just Vision in Noninfectious UveitisImproving More Than Just Vision in Noninfectious UveitisResearch. JAMA Ophthalmology. 2017;135(6):518-9.

Lee K, Bajwa A, Freitas-Neto CA, Metzinger JL, Wentworth BA, Foster CS. A comprehensive review and update on the non-biologic treatment of adult noninfectious uveitis: part I. Expert Opin Pharmacother. 2014;15(15):2141-54.

Ozdal PC, Berker N, Tugal-Tutkun I. Pars Planitis: Epidemiology, Clinical Characteristics, Management and Visual Prognosis. J Ophthalmic Vis Res. 2015;10(4):469-80.

Descargas

Publicado

2020-02-24 — Actualizado el 2020-09-09

Versiones

Cómo citar

León-Céspedes, C., Espinoza-Mora, M. del R., Antillón-Flores, F. ., Bolaños-Araya, N., Chan-Chen, H., Mena-González, H. ., Runnebaum-Jiménez, A., Jiménez-Solís, R., Pacheco-Salazar, A., Evans-Tinoco, M., & León-Bratti, M. P. (2020). Recomendaciones médicas para uveítis no infecciosas en adultos. Acta Médica Costarricense, 62(1), 26–37. https://doi.org/10.51481/amc.v62i1.1057 (Original work published 24 de febrero de 2020)